Search results for "Eloi"

showing 10 items of 601 documents

Influencia de los polimorfismos genéticos en la Leucemia Mieloide Crónica

2016

La leucemia mieloide crónica (LMC) es una neoplasia mieloproliferativa crónica de carácter clonal con origen en una célula madre pluripotencial común a las tres series hematopoyéticas. La historia natural de la LMC progresa desde una fase crónica relativamente benigna a la aparición de una fase terminal o de crisis blástica caracterizada por un cuadro de insuficiencia medular, similar al de las leucemias agudas y generalmente refractario al tratamiento. La enfermedad se caracteriza por la presencia de una alteración citogenética, el cromosoma Filadelfia (Ph), producto de una translocación recíproca entre los cromosomas 9 y 22 en las células hematopoyéticas, que genera el oncogén BCR/ABL, da…

leucemia mieloide crónicaimatinibSNPUNESCO::CIENCIAS MÉDICAS ::Patología::Hematología:CIENCIAS MÉDICAS ::Patología::Hematología [UNESCO]
researchProduct

A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.

2015

Background: Na+/H+ exchanger-1 (NHE-1) is involved in pH regulation and is up-regulated in different malignancies. Activation of NHE-1 is one way for allowing cells to avoid intracellular acidification and protect them against apoptosis. Inhibitors of NHE-1 are able to decrease intracellular pH and induce apoptosis. Some statins can also act by partial inhibition of NHE-1. This review presents progress in understanding the mechanisms of action of these inhibitors, connections with certain genetic mutations and acquired treatment resistance, as well as new patents on them. Methods: A MEDLINE search for original and review articles using key terms, Na+/H+ exchanger, leukemia, cariporide, and …

lovastatinlcsh:MedicineApoptosisPharmacologyGuanidinesAmiloridep-glycoproteinhemic and lymphatic diseasesDrug InteractionsSulfonesCation Transport ProteinsSodium-Hydrogen Exchanger 1leukemiaMyeloid leukemiaHydrogen-Ion ConcentrationSorafenibUp-RegulationLeukemiaLeukemia Myeloid AcuteImatinib MesylateSignal transductionTyrosine kinasemedicine.drugSignal TransductionSorafenibNiacinamideisoprenylationSodium-Hydrogen Exchangersbcr/ablAntineoplastic AgentsGenes ablGeneral Biochemistry Genetics and Molecular BiologystatinsPatents as TopicCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase Inhibitorscariporidena+/h+ exchangerTumor hypoxiabusiness.industryPhenylurea Compoundslcsh:ROsmolar Concentrationintracellular phmedicine.diseaseImatinib mesylatefms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3MutationCancer researchTumor Hypoxiaflt3/itdHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessHeme Oxygenase-1DNA DamageBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
researchProduct

Essential Oil Composition of Alluaudia procera and in Vitro Biological Activity on Two Drug-Resistant Models

2019

Drug resistance is a major obstacle in antibiotic and antitumor chemotherapy. In response to the necessity to find new therapeutic strategies, plant secondary metabolites including essential oils (EOs) may represent one of the best sources. EOs in plants act as constitutive defenses against biotic and abiotic stress, and they play an important role in the pharmacology for their low toxicity, good pharmacokinetic and multitarget activity. In this context, natural products such as EOs are one of the most important sources of drugs used in pharmaceutical therapeutics. The aim of this paper was to identify the chemical composition of the essential oil of Alluaudia procera leaves, obtained by hy…

medicine.drug_classAntibioticsPharmaceutical ScienceContext (language use)Drug resistancePharmacologyBiologymedicine.disease_causeSettore BIO/19 - Microbiologia Generaleessential oilAnalytical Chemistrylaw.inventionDidiereaceaelcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryPharmacokineticslawDrug DiscoverymedicineSettore BIO/15 - Biologia FarmaceuticaPhysical and Theoretical ChemistryEssential oilacute myeloid leukemia cell030304 developmental biology0303 health sciences030306 microbiologyAbiotic stressOrganic ChemistryBiological activitySettore CHIM/06 - Chimica Organicasucculent plantsChemistry (miscellaneous)Staphylococcus aureusSettore BIO/03 - Botanica Ambientale E ApplicataSettore BIO/14 - FarmacologiaMolecular MedicineMolecules
researchProduct

Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells

2021

Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular functions regulated the sensitivity or resistance of cancer cells to crizotinib. Transcription factor binding motif analyses in gene promoters divulged two transcription factors possibly regulating the expression of these genes, i.e., RXRA and GATA1, which are important for leukemia and erythroid development, respectively. COMPARE analyses also implied that cell lines of various cancer types displayed varying degr…

medicine.drug_classPharmaceutical Scienceacute myeloid leukemiaArticletranscriptomicsPharmacy and materia medicaDrug Discoverytyrosine kinase inhibitorsmedicineCytotoxic T cellnetwork pharmacologyddc:610biologyCrizotinibdrug repurposingChemistryTopoisomeraseRMyeloid leukemiaCell cyclemedicine.diseaseALK inhibitorRS1-441multiple myelomaLeukemiaCancer cellbiology.proteinCancer researchMolecular MedicineMedicinemedicine.drug
researchProduct

Cardiorenal syndrome followed by acute hepatitis C in a patient with acute myeloid leukemia

1969

SUMMARY Cardiorenal syndrome involves altering cardiac and renal function. These patients frequently develop resistance to diuretic therapy, so that ultrafiltration should be applied in emergency for saving them. Concomitant presence of an active hematologic malignancy represents an important complicating factor. We present the case of an elderly patient with acute myeloid leukemia, appeared on the background of myelodysplastic syndrome who, during marrow aplasia occurred after the first course of induction chemotherapy, developed a cardiorenal syndrome, which required repeated sessions of hemodialysis. Complete hematologic remission and efficiency of fluid depletion therapy allowed the sec…

medicine.medical_specialtyAcute leukemiaAcute leukemiabusiness.industrymedicine.medical_treatmentCardiorenal syndromeMyeloid leukemiaRenal functionInduction chemotherapyCase ReportGeneral MedicineCardiorenal syndromeAplasiamedicine.diseaseGastroenterologyCholesterolInternal medicineConcomitantHemodialysismedicineHemodialysisAcute hepatitisIntensive care medicinebusinessPakistan Journal of Medical Sciences
researchProduct

Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with M…

2005

Abstract In advanced BCR-ABL-positive leukemia, combination of chemotherapy with imatinib is expected to result in better reduction of leukemia cell load and may delay or offset clonal selection of resistant leukemia cells, thus improving the survival. We carried out a prospective phase I/II combination trial for patients (pts) with myeloid blast crisis of chronic myelogenous leukemia (CML). Pts were treated with imatinib+mitoxantrone/etoposide in four cohorts starting from mitoxantrone 10mg/m2/d and etoposide 100 mg/m2/d for 2 or 3 consecutive days and start of imatinib 600mg/d from day 15 (coh. 1 and 2) or from day 1 (coh. 3 and 4, respectively). After hematologic reconstitution following…

medicine.medical_specialtyChemotherapyMitoxantronebusiness.industrymedicine.medical_treatmentImmunologyMyeloid leukemiaCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyTransplantationImatinib mesylateInternal medicineCytarabineMedicinebusinessEtoposidemedicine.drugChronic myelogenous leukemiaBlood
researchProduct

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive …

2005

Abstract Introduction: Response to first induction therapy is one of the most important prognostic factors in patients with adult myeloid leukemia (AML). Induction of CR or PR is the primary aim in these patients. Methods: Between 1993 and 2005 225 consecutive patients (median age: 48.4 yrs, range 16–60 yrs) treated within the AMLHD93 (n=45), AMLHD98A (n=157) and AMLSG 05-04 (n=23, still active) trials were evaluated. All patients had primary refractory AML after one cycle of ICE. The different salvage therapies were as follows: AMLHD93 sequential-HAM (S-HAM) for patients <55 years of age [cytarabine 3g/m2 bid. days 1,2,8,9, mitoxantrone 10mg/m2 days 3,4,10,11], HAM for patients >=55 …

medicine.medical_specialtyGemtuzumab ozogamicinmedicine.medical_treatmentImmunologySalvage therapyHematopoietic stem cell transplantationBiochemistryGastroenterology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicine030304 developmental biology0303 health sciencesMitoxantronebusiness.industryMyeloid leukemiaCell BiologyHematologyOdds ratio3. Good healthSurgeryTransplantation030220 oncology & carcinogenesisCytarabinebusinessmedicine.drugBlood
researchProduct

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature

2004

Recombinant human erythropoietin (rHuEPO) is an effective treatment for the anaemia that occurs secondary to various conditions, but its role in myelofibrosis with myeloid metaplasia (MMM) is not well established. rHuEPO, at an initial dose of 10 000 U thrice a week, was given to 20 patients with MMM and anaemia. Complete response (CR) was defined as transfusion cessation with normal haemoglobin (Hb) levels and partial response (PR) as a transfusion decrease > or =50% and Hb > 10 g/dl maintained for at least 8 weeks. Nine patients (45%) showed a favourable response to treatment, including four CR and five PR, four of whom have maintained their response at a median follow-up of 12.5 months (…

medicine.medical_specialtyMyeloidHematologybusiness.industryAnemiaHematologymedicine.diseaseResponse to treatmentGastroenterologymedicine.anatomical_structureErythropoietinTransfusion requirementMetaplasiaInternal medicineImmunologyMedicinemedicine.symptombusinessMyelofibrosismedicine.drugBritish Journal of Haematology
researchProduct

Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospit…

2012

Invasive fungal disease (IFD) causes increasing morbidity and mortality in haematological cancer patients. Reliable cost data for treating IFD in German hospitals is not available. Objective of the study was to determine the institutional cost of treating the IFD. Data were obtained by retrospective chart review in German hospitals. Patients had either newly diagnosed or relapsed acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS). Direct medical cost was calculated from hospital provider's perspective. A total of 108 patients were enrolled at 5 tertiary care hospitals, 36 IFD patients and 72 controls. The vast majority of IFD patients (74%) were diagnosed with invasive aspergil…

medicine.medical_specialtyMyeloidbusiness.industryMyelodysplastic syndromesRetrospective cohort studyDermatologyGeneral MedicineAspergillosismedicine.diseaseIndirect costsInfectious DiseasesInvasive fungal diseasePharmacotherapymedicine.anatomical_structureInternal medicinemedicineYoung adultbusinessIntensive care medicineMycoses
researchProduct

Pubertal maturation in girls treated for childhood acute leukaemia.

1991

Eleven girlds treated during childhood for acute leukaemia were followed up during their pubertal development. At each examination weight, height, pubertal stage, FSH, LH, oestradiol, testosterone, androstenedione and dehydroepiandrosterone sulphate levels were evaluated. Clinical and endocrinological studies were performed according to age and pubertal stage and compared to those of healthy girls matched for age and pubertal stage. Results showed that pubertal maturation and gonadal function were not affected by oncotherapy; however menarche was attained earlier. Early menarche was explained by the overweight of treated girls during early puberty. No evidence of early hypothalamic activati…

medicine.medical_specialtyOverweightPubertal stageEarly menarcheInternal medicineMedicineEndocrine systemHumansAndrostenedioneChildTestosteroneMenarchebusiness.industryBody WeightPubertyAge FactorsPrecursor Cell Lymphoblastic Leukemia-LymphomaBody HeightHormonesLeukemia Myeloid AcuteEndocrinologyEl NiñoChild PreschoolPediatrics Perinatology and Child HealthMenarcheFemalemedicine.symptombusinessFollow-Up StudiesEuropean journal of pediatrics
researchProduct